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ABSTRACT
Objective: Kallikrein 5 (KLK5), which is frequently observed in normal cervico-vaginal 
fluid, is known to be related to prognosis in several solid tumors. We investigated the 
prognostic significance of KLK5 in uterine cervical cancer using tumor tissue microarray and 
immunohistochemistry staining.
Methods: We analyzed samples of 165 patients with uterine cervical cancer who received 
definitive radiation therapy between 2004 and 2012. We divided patients into two groups 
stratified by their KLK5 activity by immunohistochemistry staining: negative/weak (0–1+) 
(n=120 patients) and moderate/strong (2–3+) group (n=45 patients). Patient and tumor 
characteristics, patterns of failure, and survival outcomes were compared. Univariable and 
multivariable analyses were performed to identify prognostic factors.
Results: Patients with KLK5 2–3+ were younger (median: 52 vs. 60 years) and had frequent 
paraaortic lymph node involvement (40.0% vs. 18.3%) than those with KLK5 0–1+. With a 
median follow-up of 60.8 (interquartile range, 47.5–77.9) months, patients with KLK5 2–3+ 
had inferior 5-year locoregional recurrence-free survival and distant metastasis-free survival 
of 61.7% (vs. 77.5% in KLK5 0–1+ group) and 59.4% (vs. 72.8% in the KLK5 0–1+ group), 
respectively (all p<0.05). KLK5 2–3+ expression retained its significance after adjusting for 
other well-known prognostic factors of tumor size and stage in multivariable analysis.
Conclusions: KLK5 overexpression is associated with the aggressiveness of cervical cancer 
and may underlie the diminished response to conventional treatments. Therefore, KLK5 
could be a reliable prognostic factor in cervical cancer.
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INTRODUCTION
Cervical cancer ranks second in terms of incidence globally and seventh in Korea [1], with 
approximately 10 times lower rates in Western Europe and North America [2,3]. Although the 
incidence rate of cervical cancer has been declining worldwide over the last several decades 
[3,4], it is increasing in younger Korean populations [4,5].
Radiation therapy (RT) is the main treatment for both advanced (III–IVA) and early (IB–IIB) stages 
of cervical cancer [6]. Technological advances in RT including image-guided brachytherapy and 
radio-sensitizing drugs have significantly improved treatment outcomes, with local control rates 
> 90% and 5-year overall survival rates of 80% [7,8]. However, some patients do not respond to 
conventional treatments or relapse shortly afterwards. Some biologic markers, such as tumor-
related leukocytosis [9], receptors (EPHA4, ENDRA, and NR2C1), micro RNAs (miR-203, and 
miR-30b) [10], transcription factors (E2F, E2F4, ETS1, and CULT1) [11], and other proteins 
(PARP1, CDK1, WNK1, and CRYAB) [12] as well as several clinicopathologic factors including 
Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage, tumor size, and lymph 
node status have been suggested to identify patients who are at the greatest risk of recurrence.
As a family of 15 genes on chromosome 19q13.4, kallikreins (KLKs) are trypsin- or 
chymotrypsin like proteases that are expressed in not only human cervico-vaginal fluid 
[13,14] but also other physiologic conditions including skin desquamation [15], and brain 
development [16]. Under normal physiological conditions, proteolytic cascades associated with 
KLKs is known to be responsible for corneocytes desquamation within skin layers [15] and 
antimicrobial effects by cleavage of the antimicrobial human cathelicidin protein hCAP-18 in 
cervico-vaginal fluid [17,18]. On the contrary, many previous reports regarding KLKs advocated 
that KLKs could regulate both tumor progression and suppression in various aspects [19]. 
Among various contributions of KLK family in tumor growth, KLK5 itself has several roles in 
cancer progression. Firstly, KLK5 promotes tumor proliferative signaling with an activation of 
growth-factor signaling pathway, such as insulin-like growth factor signaling [20,21]. KLK5 is 
also known to cleave extracellular matrix components, collagen, fibronectin, and laminin which 
could provoke cancer invasion and metastasis [20]. Lastly, KLK5 also degrades and activates 
cathelicidin-derived antimicrobial peptide, a key component of innate immunity, resulting 
in cancer cell immune evasion [17,22]. Taken together, KLK5 might be closely relevant to 
tumorigenic condition which brings an attention as a potential therapeutic target.
There is little evidence on the prognostic value of KLKs in cervical cancer, [14] although 
there are several reports regarding the prognostic value of KLKs in other solid tumors, such 
as prostate, breast, ovarian cancer, and hepatocellular carcinoma [23-26]. In addition, KLK5 
is expected to have a prognostic value in ovarian cancer, another female reproductive tract 
malignancy [27] and prostate cancer [21]. To this end, in the present study, we carried out 
immunohistochemical analysis of clinical specimens using tissue microarray to identify the 
role of KLK5 in tumor aggressiveness and prognosis of uterine cervical cancer.
MATERIALS AND METHODS
1. Tumor specimens
Paraffin-embedded specimens from 165 patients with uterine cervical carcinoma who 
received definitive RT were obtained from Yonsei Cancer Center archives. Inclusion criteria 
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were histologically confirmed cervical carcinoma and RT to intact uterus between January 
2004 and December 2012. Patients 1) who had recurrent or metastatic disease, 2) who 
had a history of other malignancies, or 3) who had missing follow-up data were excluded. 
The protocol was approved by the Institutional Review Board (No. 4-2015-0454) or human 
research ethics committee at each participating center and complied with country-specific 
regulatory requirements. The study was conducted in accordance with the provisions of the 
Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was 
waived because the revision of the Bioethics and Safety Act of Korea was endorsed in 2013.
2. Treatment
All patients were treated with external beam RT and high-dose rate intracavitary 
brachytherapy. Detailed procedures of external beam RT and intracavitary brachytherapy 
were described previously. [7,9,28,29] One hundred and thirty-one patients without 
lymph node involvement received whole pelvis RT; 14 patients with paraaortic lymph node 
involvement were treated with extended-field RT covering up to T11/12 or T12/L1 [28], 
and 20 patients received a semi-extended-field RT from the superior border to the upper 
margin of L2. Regarding intracavitary brachytherapy, a total dose of 30 Gy in 6 fractions (88 
patients) or 10 fractions (50 patients) was most commonly prescribed at point A. After weekly 
pelvic examination, midline block at 27–36 Gy was applied in 100 patients [7]. After 2000, 
concurrent chemo-RT was routinely performed [29].
3. Tissue microarray construction
Resected tumor specimens were fixed in 10% buffered formalin and embedded in paraffin 
according to a standard protocol [30]. All available hematoxylin and eosin-stained slides 
were reviewed, and the most representative tumor areas without necrosis were marked on the 
slides. Formalin-Fixed Paraffin-Embedded blocks for tissues corresponding to the marked 
areas were sampled using the Quick-Ray Tissue Microarrayer (Unitma, Seongnam, Korea).
4. Immunohistochemistry
Immunohistochemical analysis was performed using a compact polymer method (Bond 
Intense Detection Kit; Leica Biosystems, Newcastle-upon-Tyne, UK). The 4-μm-thick, FFPE 
sections were deparaffinised and dehydrated with xylene and then rehydrated in a graded 
series of alcohol. Endogenous peroxidase activity was quenched by incubation in 0.3% 
hydrogen peroxide and methanol for 20 minutes. Following a rinse in phosphate-buffered 
saline, sections in citrate buffer (0.01 M, pH 6.0) were irradiated in a microwave oven for 20 
min and allowed to cool at room temperature. The sections were incubated with polyclonal 
anti-KLK5 antibody (1:100; R&D Systems, Minneapolis, MN, USA), and immunoreactivity 
was visualized using the Peroxidase/DAB EnVision+ Detection System (Dako, Carpinteria, 
CA, USA). The sections were counterstained with haematoxylin and covered with cover slips 
for observation under a microscope. The positive control was normal skin tissue; the negative 
control was prepared by substituting non-immune serum for the primary antibody, and no 
staining was detected [31].
Immunoreactivity was independently scored by 2 board-certified pathologists who were 
blinded to clinicopathological information. The staining positivity in tumor cells was 
scored on a scale of 0–3 as follows: 0, negative; 1, weak; 2, moderate; and 3, intense. The 
percentage of positive tumor cells was classified into four categories: 1, <10%; 2, 10%–24%; 
3, 25%–49%; and 4, ≥50%. The final score was calculated by multiplying the intensity and 
percentage scores. Immunoreactivity was then classified as negative (score=0), weakly 
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positive (score=1 or 2), moderately positive (score=3–6), and strongly positive (score=8–12) 
(Fig. 1). Disagreements between the two pathologists were resolved by discussion. For further 
analysis, we categorized patients into 2 groups regarding immunoreactivity; 0–1+ group 
(negative to weakly positive) and 2–3+ group (moderately to strongly positive).
5. Statistical analysis
Either χ2 test or Mann-Whitney U test was employed to compare the categorical or continuous 
data between 2 groups. The response rate was defined as the proportion of responders 
(complete and partial response) among all patients. Locoregional recurrence-free survival 
(LRFS) and distant metastasis-free survival (DMFS) were determined from the date of initial 
diagnosis to the date of each event or death from any cause (whichever came first). Survival 
was estimated with the Kaplan-Meier method, and comparisons were performed with the 
log-rank test. The Cox proportional hazards model was used to analyze the significance 
of prognostic factors and bootstrapping method with 1,000 resampling was performed to 
confirm covariate independence in multivariable analysis. Statistical significance was set at 
a 2-sided p-value <0.05. Statistical analyses were performed using SPSS version 25.0.0 (IBM 
Corp., Armonk, NY, USA).
RESULTS
The study population comprised 165 patients (median age, 57) with stage IA–IVA uterine 
cervical carcinoma, and the baseline characteristics are summarized in Table 1. Most 
patients (n=147, 84.1%) were histologically diagnosed with squamous cell carcinoma. With 
a median tumor size of 4.5 (interquartile range [IQR], 3.0–6.0) cm, half of the patients had 
FIGO stage III–IVA disease. Patients received definitive RT with (n=142, 86.1%) or without 
(n=23, 13.9%) concurrent platinum-based chemotherapy. Among 165 patients, most patients 
were categorized into the KLK5 0–1+ group (n=120, 72.7%), and 45 patients (27.3%) were 
categorized into the KLK5 2–3+ group. Patients in the KLK5 2–3+ group were younger (median 
52 years), had frequent paraaortic lymph node involvement at diagnosis (n=18, 40.0%), and 
were more frequently treated with concurrent chemo-RT (n=43, 95.6%). Additionally, 18 
patients (40.0%) in the KLK5 2–3+ group presented with tumor-related leukocytosis defined 
as leukocyte exceeding 9,000/μL at 2 separate occasions without infection compared to the 22 
patients (18.3%) in the KLK5 0–1+ group that exhibited tumor-related leukocytosis at baseline 
(p=0.004). Moreover, 6 patients with KLK5 3+ had a larger tumor size (median, 6.6 cm), and 5 
of them presented with advanced disease of FIGO stage III–IVA.
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Negative Weakly positive Moderately positive Strongly positive
Fig. 1. Expression of human KLK5 in uterine cervical cancer tissue detected by tissue microarray and 
immunohistochemistry. 
KLK5, kallikrein 5.
There was no difference in the rate of complete response after RT between the KLK5 0–1+ and 
2–3+ groups (95.8% vs. 91.1%, p = 0.258). However, tumors in the KLK5 3+ group showed 
the lowest complete response rate (66.7%) than those in the KLK5 0–1+ and KLK5 2+ group 
(95.8% and 94.9%, respectively, p=0.036). Detailed information on patterns of failures is 
summarized in Fig. 2. The overall progression was more frequently observed in the KLK5 
2–3+ group (53.3%) than in the KLK5 0–1+ group (24.2%, p<0.001). There were 40 patients 
(75.5% of disease progression in the entire cohort) who developed distant metastases. 
Specifically, patients with tumor expressing KLK5 2–3+ had a higher risk of distant metastasis 
than patients in the KLK5 0–1+ group (37.8% vs. 19.2%, p=0.021). Twenty-one patients of the 
entire cohort experienced local or regional recurrences. Local recurrences were observed in 
7 patients (5.8%, Fig. 2A) in the KLK5 0–1+ group and 5 patients (11.1%, Fig. 2B) in the KLK5 
2–3+ group; regional recurrences were observed in 4 patients (3.3%, Fig. 2A) in the KLK5 
0–1+ group and 8 patients (17.8%, Fig. 2B) in the KLK5 2–3+ group (all p<0.05).
With a median follow-up period of 60.8 (IQR, 47.5–77.9) months, 5-year LRFS and DMFS rates 
for the entire cohort were 73.1% and 69.0%, respectively. There was a significant difference 
5/11https://ejgo.org https://doi.org/10.3802/jgo.2020.31.e78
KLK5 and poor prognosis in cervical cancer
Table 1. Baseline characteristics stratified by KLK5 expression intensity based on immunohistochemistry staining
Variables Total (n=165) KLK5 0–1+ (n=120) KLK5 2–3+ (n=45) p
Age (yr) 57 [48–67] 60 [49–68] 52 [46–61] 0.008
Hb (mg/dL) 0.085
<10 35 (21.2) 21 (17.5) 14 (31.1)
≥10 130 (78.8) 99 (82.5) 31 (68.9)
Histology 0.782
SCC 147 (89.1) 106 (88.4) 41 (91.1)
ADC 13 (7.9) 9 (7.5) 4 (8.9)
ADSCC 4 (2.4) 4 (3.3) 0 (0.0)
Clear cell 1 (0.6) 1 (0.8) 0 (0.0)
Differentiation 0.913
WD 7 (4.2) 5 (4.2) 2 (4.4)
MD 13 (7.9) 9 (7.5) 4 (8.9)
PD 15 (9.1) 12 (10.0) 3 (6.7)
Not available 130 (78.8) 94 (78.3) 36 (80.0)
PET evaluation 0.158
Yes 139 (84.2) 98 (81.7) 41 (91.1)
Size (cm) 4.5 [3.0–6.0] 4.0 [3.0–5.7] 5.0 [3.4–6.2] 0.113
<4 97 (58.8) 75 (62.5) 22 (48.9) 0.155
≥4 68 (41.2) 45 (37.5) 23 (51.1)
FIGO stage* 0.863
I–II 79 (47.9) 58 (48.3) 21 (46.7)
III–IV 86 (52.1) 62 (51.7) 24 (53.3)
LN metastasis 0.015
No 90 (54.5) 68 (56.7) 22 (48.9)
Pelvic 58 (35.2) 45 (37.5) 13 (28.9)
Paraaortic 17 (10.3) 7 (5.8) 10 (22.2)
TRL 0.004
No 125 (75.8) 98 (81.7) 27 (60.0)
Yes 40 (24.2) 22 (18.3) 18 (40.0)
Treatment 0.041
RT alone 23 (13.9) 21 (17.5) 2 (4.4)
CCRT 142 (86.1) 99 (82.5) 43 (95.6)
Values are presented as number of patients (%) or median [interquartile range].
ADC, adenocarcinoma; ADSCC, adenosquamous cell carcinoma; CCRT, concurrent chemoradiation therapy; 
FIGO, Fédération Internationale de Gynécologie et d'Obstétrique; Hb, hemoglobin; KLK5, kallikrein 5; LN, lymph 
node; MD, moderately differentiated; PD, poorly differentiated; PET, positron emission tomography; RT, radiation 
therapy; SCC, squamous cell carcinoma; TRL, tumor-related leukocytosis; WD, well differentiated.
*FIGO stage refers to the revised 2018 FIGO staging.
in LRFS between the 2 groups (5-year LRFS: KLK5 0–1+ and 2–3+ group, 77.5% and 61.7%, 
respectively, Fig. 3A). KLK5 2–3+ expression was a significant unfavorable factor for LRFS 
after adjusting for age, hemoglobin level, size, stage, lymph node involvement, treatment 
modality, and response after treatment (hazard ratio [HR]=2.15; 95% confidence interval 
[CI]=1.10–4.20; p=0.026; Table 2). A similar trend was also observed in the DMFS of the 
patients in the 2 groups; the KLK5 2–3+ group had inferior 5-year DMFS outcomes (59.4%) 
compared to the KLK5 0–1+ group (72.8%, Fig. 3B). In addition, the inferior DMFS outcomes 
of the KLK5 2–3+ group were observed consistently in both FIGO I–II (71.4% vs. 77.0% in 
the KLK5 0–1+ group) and FIGO III–IV (48.7% vs. 69.1% in the KLK5 0–1+ group) stages 
(Supplementary Fig. 1). Multivariable analysis demonstrated that KLK5 overexpression was 
a significant independent predictor of DMFS (HR=1.81; 95% CI=1.29–3.34; p=0.021, Table 3) 
along with response after treatment.
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Fig. 3. (A) LRFS and (B) DMFS stratified by KLK5 immunoreactivity. 
DMFS, distant metastasis-free survival; KLK5, kallikrein 5; LRFS, locoregional recurrence-free survival.
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Table 2. Unadjusted and adjusted HR and 95% CI for locoregional free survival in 165 patients with uterine 
cervical cancer
Variables HR† 95% CI p HR‡ 95% CI p
Age (yr)
<57 vs. ≥57 0.49 0.27–0.91 0.023 0.50 0.24–1.03 0.061
Hb (mg/dL)
≥10 vs. <10 1.49 0.77–2.89 0.233 1.12 0.53–2.38 0.771
Tumour size (cm)
<4 vs. ≥4 1.67 0.94–2.98 0.083 0.82 0.38–1.74 0.600
Histologic grade*
WD/MD vs. PD 0.98 0.41–2.38 0.970
FIGO stage
I–II vs. III–IVA 2.02 1.10–3.71 0.023 5.22 1.71–15.97 0.004
LN metastasis
No vs. Yes 1.41 0.79–2.51 0.248 0.75 0.25–1.17 0.121
Treatment
RT vs. CCRT 0.75 0.35–1.60 0.450 0.52 0.22–1.23 0.137
Response after 
treatment
CR vs. non–CR 28.17 11.84–66.98 <0.001 15.67 5.91–41.59 <0.001
KLK5
0–1+ vs. 2–3+ 2.14 1.19–3.85 0.011 2.15 1.10–4.20 0.026
The foreparts of the parentheses were set as the reference groups in the multivariable analysis.
CCRT, concurrent chemoradiation therapy; CI, confidence interval; CR, complete response; FIGO, Fédération 
Internationale de Gynécologie et d'Obstétrique; Hb, haemoglobin; HR, hazard ratio; KLK5, kallikrein 5; LN, lymph 
node; MD, moderately differentiated; PD, poorly differentiated; RT, radiation therapy; WD, well differentiated.
*Only available for 35 patients in the entire cohort; †Unadjusted; ‡Mutually adjusted for seven variables after 
bootstrapping with 1,000 resamples.
Table 3. Unadjusted and adjusted HR and 95% CI for distant metastasis-free survival in 165 patients with uterine 
cervical cancer
Variables HR† 95% CI p HR‡ 95% CI p
Age (yr)
<57 vs. ≥57 0.50 0.28–0.89 0.018 0.52 0.27–1.01 0.053
Hb (mg/dL)
≥10 vs. <10 1.38 0.74–2.60 0.315 1.37 0.65–2.91 0.410
Tumour size (cm)
<4 vs. ≥4 1.97 1.13–3.42 0.016 1.68 0.85–3.30 0.134
Histologic grade*
WD/MD vs. PD 1.10 0.42–2.87 0.849
FIGO stage
I–II vs. III–IVA 1.49 0.85–2.61 0.160 1.60 0.50–5.20 0.431
LN metastasis
No vs. Yes 1.26 0.73–2.18 0.410 0.67 0.24–1.89 0.448
Treatment
RT vs. CCRT 0.86 0.40–1.83 0.696 0.48 0.21–1.12 0.090
Response after 
treatment
CR vs. non-CR 5.51 2.30–13.23 <0.001 2.97 1.08–8.20 0.035
KLK5
0–1+ vs. 2–3+ 2.01 1.15–3.53 0.015 1.81 1.29–3.34 0.021
The foreparts of the parentheses were set as the reference groups in the multivariable analysis.
CCRT, concurrent chemoradiation therapy; CI, confidence interval; CR, complete response; FIGO, Fédération 
Internationale de Gynécologie et d'Obstétrique; Hb, haemoglobin; HR, hazard ratio; KLK5, kallikrein 5; LN, lymph 
node; MD, moderately differentiated; PD, poorly differentiated; RT, radiation therapy; WD, well differentiated.
*Only available for 35 patients in the entire cohort; †Unadjusted; ‡Mutually adjusted for seven variables after 
bootstrapping with 1,000 resamples.
DISCUSSION
Histologically, RT has been the mainstay of treatment for patients with cervical cancer due to 
its radio-sensitivity. However, the unknown biological differences in radio-resistance of non-
responders who suffered from subsequent recurrences have been an obstacle for a cure. In 
the current study, we have demonstrated that KLK5 overexpression (KLK5 2–3+) detected in 
27.2% of patients through a tissue microarray cohort was associated with poor RT response, 
resulting in a frequent locoregional recurrence and distant metastasis. Taken together, KLK5 
overexpression could be a potential prognostic factor.
Certain KLKs including KLK5 are co-expressed in human cultured cervical cancer cell lines 
[13,14]. A proteolytic cascade of KLK5 elicits an activation of tumor proliferating signaling, 
enhancing cancer invasion or metastasis, and inducing immune evasion of cancer cell 
[19]. As an initiator for other KLKs, KLK5 has been identified as a preferential activator of 
protease-activated receptor-2 (PAR-2) [32,33], a receptor that is upregulated in cervical cancer 
and contributes to cancer proliferation [34]. Although we could not evaluate the expression 
of PAR-2 in the current cohort, further investigations incorporating KLK5 and PAR-2 in 
cervix cancer should be needed to clarify the relationship. In addition to extracellular matrix 
cleavage of KLK5 resulting in cancer invasion and metastasis [20,21], Mukai et al. [26] 
reported that KLK5 mediates oncogenic downstream signal through proteolytic activation of 
hepatocyte growth factor activator, which activates hepatocyte growth factor/scatter factor 
and tyrosine kinase MET signaling, which in turn, initiates invasion and metastasis [35]. 
Given the association between KLK5 and carcinogenesis/cancer progression [19], we can 
speculate that KLK5 overexpression could be related to aggressive tumor behavior in cervical 
cancer. Despite the limited number of patients in the KLK5 3+ group, the patients presented 
with advanced and larger tumor size and consequently resulted in lower rate of complete 
response after RT than those in the KLK5 0–2+ group.
The mechanistic link between KLKs and immune evasion has only recently begun to 
emerge. KLKs can affect the innate immune response preferable to tumor progression as 
extrinsic complement-related factors [36] and activators of transforming growth factor 
[37]. Specifically, KLK5 alters the tumor microenvironment by inducing the activation of 
the cathelicidin antimicrobial peptide LL-37, which stimulates neutrophils, monocytes, and 
T-lymphocytes [17,22]. Thus, continuous leukocyte recruitment to KLK5-overexpressing 
tumors could be characterized by changes in blood leukocyte content and hypermetabolic 
bone marrow in PET images. We previously reported that tumor-related leukocytosis in 
uterine cervical cancer is a distinct clinical entity presenting with an advanced stage at a 
younger age that does not respond well to standard treatments [9]. In that study, 16.2% 
of patients (n=398) with stage IA–IVA cervical cancer (n=2,456) who received definitive RT 
exhibited tumor-related leukocytosis, accompanied by an increased risk of locoregional 
recurrence, distant failure, and poor overall survival. In the current study, we also observed 
frequent tumor-related leukocytosis in KLK5 2–3+ group (40.0%) compared to KLK5 0–1+ 
group (18.3%). Although the exact contribution of KLK5 in tumor-related leukocytosis in 
tumor microenvironment needs to be explored, this indicates that the poor prognosis of 
tumor-related leukocytosis might be one of the phenotypes associated with KLK5 expression.
KLK5 was recently suggested as a potential biomarker in ovarian cancer [27]; in a study of 52 
patients, higher KLK5 levels in serum and ascites were associated with worse progression-free 
survival. In addition, KLK5 protein was only detected in patients with ovarian cancer, but not in 
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normal female subjects and patients with benign ovarian tumors. While no currently available 
drugs target KLK5, recent researches have taken preliminary steps toward identifying selective 
pharmacological inhibitors of this protease. Based on our findings, we anticipate that direct/
indirect targeting of KLK by selective synthetic KLK inhibitors and modulators will be an 
effective therapeutic strategy that can be combined with standard chemo-radiotherapy [38] or 
immune checkpoint inhibitors, which is especially promising considering the important role of 
KLKs in the immune response. As in the case of prostate-specific membrane antigen targeted 
by antitumor vaccines [39], KLK serine proteases are potential targets for immunotherapy.
Our study has several limitations. First, owing to the limited number of available tissue 
microarray, there are issues regarding selection bias and statistical significance of the results. 
However, to our knowledge, this study has the largest clinical data accompanied with tissue 
microarray assay thus far on cervical cancer treated with RT. In addition, we only evaluated 
the immunoreactivity of KLK5 among KLKs. Given that KLK5 activation is the first step 
in activating multiple KLKs, identifying KLK5s with immunohistochemistry staining may 
be an efficient and effective method for stratifying patients at higher risk for poor survival. 
Lastly, lack of surgical specimen in the current analysis might not be able to provide the 
information on tumor heterogeneity. However, biopsy specimen could provide essential 
information in the current study since we aimed to identify the role of KLK5 in not only 
tumor characteristics but also RT response.
In summary, we demonstrated that KLK5 directly affects an aggressive tumor behavior 
and the poor treatment response observed in a subset of cervical cancer patients. KLK5 
overexpression detected by immunohistochemistry can identify high-risk cervical cancer 
patients who require more intensive treatment in clinical trials, although further studies are 
needed to clarify the involvement of KLK5 in tumor progression and to assess its value as a 
biomarker for predicting prognosis or treatment response or as a therapeutic target.
SUPPLEMENTARY MATERIAL
Supplementary Fig. 1
DMFS in the FIGO stage I–II (A) and III–IV (B) groups stratified by KLK5 immunoreactivity.
Click here to view
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